BCC Excision Revisited
Sponsor
Medical University of Vienna (Other)
Overall Status
Completed
CT.gov ID
NCT05853315
Collaborator
(none)
451
1
41.6
10.8
Study Details
Study Description
Brief Summary
To readdress basal cell carcinoma (BCC) in the periocular region to prove histologically controlled surgical treatment efficacy and to identify high-risk characteristics.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
451 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Long-term Results After Surgical Basal Cell Carcinoma Excision in the Eyelid Region: Revisited
Actual Study Start Date
:
Nov 12, 2019
Actual Primary Completion Date
:
Apr 1, 2023
Actual Study Completion Date
:
May 1, 2023
Outcome Measures
Primary Outcome Measures
- BCC Recurrence [mean 3-5 years]
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion criteria:
-
Patient records were reviewed for the presence of BCC and surgical excision with frozen sections control of the wound margins in the periocular region,
-
conducted between 01.01.2009 and 31.12.2019.
-
Periocular was defined as the area involving the medial and lateral canthus as well as the upper and lower eyelids.
Exclusion criteria:
-
BCCs outside of this region were excluded from this analysis,
-
as well as incomplete records.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Medical University of Vienna | Vienna | Austria | 1090 |
Sponsors and Collaborators
- Medical University of Vienna
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Reinhard Told,
Priv. Doz. Dr.,
Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT05853315
Other Study ID Numbers:
- 1997/2019
First Posted:
May 10, 2023
Last Update Posted:
May 16, 2023
Last Verified:
May 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: